Advancements in next-generation sequencing (NGS) technologies have enabled researchers to generate genome-wide data of unprecedented quality and quantity. Genomics, expression, microRNA, chromatin IP, ...
Vigil Neuroscience (VIGL) has made great progress in being able to advance its pipeline. It just reported interim results from its phase 2 IGNITE study, which used its drug iluzanebart [formerly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback